Lyell Immunopharma will present Phase 1/2 trial data on ronde-cel for large B-cell lymphoma at EHA 2026 Congress.
Quiver AI Summary
Lyell Immunopharma, Inc. announced that it will present data from its Phase 1/2 clinical trial of its CAR T-cell therapy, rondecabtagene autoleucel (ronde-cel), for relapsed or refractory large B-cell lymphoma at the upcoming European Hematology Association (EHA) 2026 Congress in Stockholm from June 11-14, 2026. The presentations will focus on updated safety analyses and translational insights regarding ronde-cel. The company is currently assessing ronde-cel in pivotal trials, including the ongoing PiNACLE trial and the Phase 3 randomized PiNACLE-H2H trial, with plans for a Biologics License Application submission in 2027. Lyell is dedicated to advancing next-generation CAR T-cell therapies and has capabilities to manufacture a substantial number of doses for commercial launch.
Potential Positives
- Lyell Immunopharma will present data from its ongoing Phase 1/2 trial of ronde-cel at the prestigious European Hematology Association Congress, enhancing its visibility in the oncology community.
- The presentations will include updated safety analysis and translational insights, potentially highlighting the therapeutic advantages of ronde-cel for patients with relapsed or refractory large B-cell lymphoma.
- Lyell is advancing its pipeline with ongoing pivotal trials that may lead to a Biologics License Application submission in 2027, indicating progress toward bringing its therapies to market.
- The company's manufacturing capacity, expected to exceed 1,200 CAR T-cell doses per year, demonstrates robust preparedness for commercial launch, which could support future revenue growth.
Potential Negatives
- Company is under scrutiny as it is linked to ongoing clinical trials, which may carry significant risks and uncertainties regarding the success of its product candidates.
- Dependence on future data presentations to impact investor confidence and validate drug efficacy may indicate current inadequacies in the existing evidence of their treatments' effectiveness.
- Delayed timelines for pivotal data reports and future Biologics License Application (BLA) submissions may raise concerns about the company's progress and operational efficiency.
FAQ
What is the focus of Lyell Immunopharma's research?
Lyell Immunopharma focuses on next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
What data will be presented at EHA 2026 Congress?
Data from the Phase 1/2 trial of rondecabtagene autoleucel in R/R large B-cell lymphoma will be presented.
When will the poster presentations take place?
The poster presentations are scheduled for June 12, 2026, at 12:45 pm EDT / 6:45 pm CEST.
What are some anticipated results from the ongoing trials?
Updated data from the ongoing PiNACLE trial is expected in the second half of 2026 with pivotal data by mid-2027.
Where can the poster presentations be accessed after the event?
The poster presentations will be available on the Science section of Lyell's website after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LYEL Insider Trading Activity
$LYEL insiders have traded $LYEL stock on the open market 9 times in the past 6 months. Of those trades, 2 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $LYEL stock by insiders over the last 6 months:
- VENTURE PARTNERS IX, LLC ARCH purchased 488,090 shares for an estimated $12,499,984
- VENTURE FUND XIII, L.P. ARCH purchased 488,090 shares for an estimated $12,499,984
- LYNN SEELY (President and CEO) has made 0 purchases and 2 sales selling 7,893 shares for an estimated $184,499.
- GARY K. LEE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 1,818 shares for an estimated $42,483.
- STEPHEN J. HILL (Chief Operating Officer) has made 0 purchases and 2 sales selling 1,345 shares for an estimated $31,430.
- VERONICA SANCHEZ BULIS (VP, Corporate Controller) sold 254 shares for an estimated $5,872
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$LYEL Revenue
$LYEL had revenues of $2K in Q1 2026. This is a decrease of -71.43% from the same period in the prior year.
You can track LYEL financials on Quiver Quantitative's LYEL stock page.
You can access data on LYEL stock through the Quiver Quantitative API.
$LYEL Hedge Fund Activity
We have seen 40 institutional investors add shares of $LYEL stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARCH VENTURE MANAGEMENT, LLC added 488,090 shares (+17.7%) to their portfolio in Q1 2026, for an estimated $9,791,085
- MILLENNIUM MANAGEMENT LLC added 400,254 shares (+682.4%) to their portfolio in Q1 2026, for an estimated $8,029,095
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 159,182 shares (+105.4%) to their portfolio in Q1 2026, for an estimated $3,193,190
- VELAN CAPITAL INVESTMENT MANAGEMENT LP added 102,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,046,119
- INVESCO LTD. added 98,649 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,036,416
- OPALEYE MANAGEMENT INC. added 79,097 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,586,685
- RENAISSANCE TECHNOLOGIES LLC added 76,921 shares (+194.8%) to their portfolio in Q1 2026, for an estimated $1,543,035
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$LYEL Analyst Ratings
Wall Street analysts have issued reports on $LYEL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/09/2025
To track analyst ratings and price targets for $LYEL, check out Quiver Quantitative's $LYEL forecast page.
$LYEL Price Targets
Multiple analysts have issued price targets for $LYEL recently. We have seen 3 analysts offer price targets for $LYEL in the last 6 months, with a median target of $44.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $45.0 on 06/03/2026
- Gil Blum from Needham set a target price of $44.0 on 05/07/2026
- Reni J. Benjamin from Citizens set a target price of $34.0 on 03/09/2026
Full Release
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that the Company will present data from its ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden, June 11–14, 2026. The data will be featured in two poster presentations covering an updated ronde-cel safety analysis and translational insights.
EHA 2026 Poster Presentations
Low-Grade CRS and ICANS with Rondecabtagene Autoleucel, a Dual-Targeting CD19/CD20 CAR T-Cell Product Candidate, in Patients with Large B-Cell Lymphoma: Updated Safety Analysis
- Poster: PF962
- Session: Large B-Cell Lymphomas – Clinical; Hall A
- Time: Friday, June 12, 12:45 pm EDT / 6:45 pm CEST
- Presenting Author: Sarah M. Larson, M.D., Associate Professor in the Division of Hematology-Oncology, David Geffen School of Medicine, UCLA
Durable Responses with Rondecabtagene Autoleucel (Dual-Targeting CD19/CD20 CAR
T-Cells) are Associated with Higher Proportion of Cytotoxic T Cells with Memory Potential in Infusion Products
- Poster: PF1097
- Session: Lymphoma Biology & Translational Research; Hall A
- Time: Friday, June 12, 12:45 pm EDT / 6:45 pm CEST
- Presenting Author: Akil Merchant, M.D., Associate Professor and Co-Director of the Lymphoma Program, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center
Ronde-cel is currently being evaluated for the treatment of R/R LBCL across two pivotal clinical trials. In the 3L+ setting, the ongoing single-arm PiNACLE trial is expected to report updated data in the second half of 2026 and pivotal data by mid-2027, setting up a subsequent Biologics License Application (BLA) submission in 2027. In the 2L setting, the Phase 3 randomized PiNACLE-H2H trial is evaluating ronde-cel against investigator’s choice of axicabtagene ciloleucel or lisocabtagene maraleucel.
The posters will be available through the Science section of the Company's website at www.lyell.com after the presentations.
About Lyell Immunopharma, Inc.
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year. To learn more, please visit www.lyell.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell's planned presentations at a medical congress; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Pablo Fenton
Associate Director, Investor Relations and Corporate Communications
[email protected]
